INO — Inovio Pharmaceuticals Balance Sheet
0.000.00%
- $141.53m
- $90.73m
- $0.22m
Annual balance sheet for Inovio Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 412 | 401 | 253 | 145 | 94.1 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 19.1 | 8.03 | 11.7 | 2.41 | 1.2 |
| Prepaid Expenses | |||||
| Total Current Assets | 471 | 448 | 315 | 153 | 97.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 24.1 | 29 | 18 | 14.5 | 11.8 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 540 | 496 | 349 | 171 | 113 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 41.7 | 65.7 | 96.9 | 42.6 | 35.3 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 78.6 | 96.3 | 126 | 53.6 | 44.7 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 461 | 400 | 222 | 117 | 68.5 |
| Total Liabilities & Shareholders' Equity | 540 | 496 | 349 | 171 | 113 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |